LYEL vs. ATAI, TYRA, OPT, BCYC, KURA, PRME, TSHA, BCAX, ABVX, and PGEN
Should you be buying Lyell Immunopharma stock or one of its competitors? The main competitors of Lyell Immunopharma include atai Life Sciences (ATAI), Tyra Biosciences (TYRA), Opthea (OPT), Bicycle Therapeutics (BCYC), Kura Oncology (KURA), Prime Medicine (PRME), Taysha Gene Therapies (TSHA), Bicara Therapeutics (BCAX), Abivax (ABVX), and Precigen (PGEN). These companies are all part of the "pharmaceutical products" industry.
Lyell Immunopharma vs. Its Competitors
Lyell Immunopharma (NASDAQ:LYEL) and atai Life Sciences (NASDAQ:ATAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.
In the previous week, atai Life Sciences had 2 more articles in the media than Lyell Immunopharma. MarketBeat recorded 3 mentions for atai Life Sciences and 1 mentions for Lyell Immunopharma. Lyell Immunopharma's average media sentiment score of 1.89 beat atai Life Sciences' score of 0.44 indicating that Lyell Immunopharma is being referred to more favorably in the media.
atai Life Sciences has a net margin of 0.00% compared to Lyell Immunopharma's net margin of -514,649.22%. Lyell Immunopharma's return on equity of -73.66% beat atai Life Sciences' return on equity.
atai Life Sciences has higher revenue and earnings than Lyell Immunopharma. atai Life Sciences is trading at a lower price-to-earnings ratio than Lyell Immunopharma, indicating that it is currently the more affordable of the two stocks.
66.1% of Lyell Immunopharma shares are held by institutional investors. Comparatively, 28.4% of atai Life Sciences shares are held by institutional investors. 22.3% of Lyell Immunopharma shares are held by insiders. Comparatively, 26.8% of atai Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Lyell Immunopharma presently has a consensus target price of $15.00, suggesting a potential upside of 53.85%. atai Life Sciences has a consensus target price of $9.00, suggesting a potential upside of 243.51%. Given atai Life Sciences' stronger consensus rating and higher probable upside, analysts clearly believe atai Life Sciences is more favorable than Lyell Immunopharma.
Lyell Immunopharma has a beta of -0.24, indicating that its share price is 124% less volatile than the S&P 500. Comparatively, atai Life Sciences has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.
Summary
atai Life Sciences beats Lyell Immunopharma on 11 of the 17 factors compared between the two stocks.
Get Lyell Immunopharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for LYEL and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LYEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lyell Immunopharma Competitors List
Related Companies and Tools
This page (NASDAQ:LYEL) was last updated on 7/13/2025 by MarketBeat.com Staff
Free LYEL Stock Alerts